Dizal Pharmaceutical Hits Day Low at CNY 47.68 Amid Price Pressure

Dizal (Jiangsu) Pharmaceutical Co., Ltd. experienced significant volatility on June 1, 2026, with the stock declining by 12.46% and reaching an intraday low of CNY 47.68. This performance starkly contrasts with the China Shanghai Composite, which saw a modest decline of 0.27% on the same day. Over the past week, Dizal's stock has dropped 11.34%, and its one-month performance reflects a decrease of 14.27%. Year-to-date, the stock has underperformed with a decline of 15.61%, while the broader market has gained 2.24%. In the last year, Dizal has reported a significant drop of 19.39%, compared to the China Shanghai Composite's impressive return of 21.22%. Financial metrics indicate challenges for the company, including a low Return on Capital Employed (ROCE) of 18.72% and a high Debt to Equity ratio. The company has faced difficulties in achieving profitability, as evidenced by negative operating profit growth over the past five years. With a market capitalization of CNY 24,168 million, Dizal remains a notable player in the miscellaneous industry, albeit with ongoing financial hurdles.